ArticleJournal of neuro-oncology2019

Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.

Todd W Miller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.